Delegates called for: improving research and innovation capacity of China's
Premier Wen Jiabao's government work report this year, proposes to develop biological Medicine Industry. In response, representatives of members of the medical and health areas to be highly concerned about, combined with "significant Drug Discovery" science and technology major projects, bio-medical technology development hot topic of drug research and innovation in improving our ability to do a good job for his views on new drug registration.
CPPCC, Shanghai Institute of Materia Medica Chinese Academy of Sciences, deputy director of the Hua-Liang Jiang expressed the hope that the State Food Drugs Drug regulatory authorities in promoting the development of a greater role to play: First, to speed up the progress of new drug review, the strict enforcement provisions of the corresponding day, based on further study the feasibility of shortening days; the second is to help our country Pharmaceutical companies Through play a greater role in international certification can be organized and targeted training courses, reference materials, can also have strong enterprises participating in international competition for fixed-point support. He also recommended that countries should "create a major new drug," the implementation of major science and technology projects developed by the tax rebate package policy; attention to the private, the private sector's technological innovation capacity building, strong innovation ability Pharmacy Business, government should provide active guidance and support.
"Promote the development of new drugs for lowering health costs, resolution of the masses 'Expensive', 'medical treatment is difficult' issue has a very key role." CPPCC National Committee members, the Chinese Centre for Disease Control and Prevention AIDS Chief Expert hua proposed that in the situation has markedly improved drug registration under the premise of improving the registration of new regulatory standards as soon as possible is a very pressing issue. In new drug research and development, food and drug supervision departments to early intervention, support enterprises to be more scientific and more normative work carried out development and production. Review of new drug development for a long time the principles of our performance as a "strict easy out", and SHAO, said: "To promote the new drug development, in ensuring the safety of the premise of truth and, as soon as possible to enter Phase I clinical trials, but in two, Phase III clinical trials must be strictly. At the same time, the risk for drug research, the relevant departments should consider the establishment of specialized commercial insurance. "He also suggested that, subject to the premise of the patent system, should support Generic The development of drugs to consider in advance of patent examination.
NPC chairman Zhao pharmaceutical step over that the food and drug supervision departments should give better play to the guiding role of registered supervision, to encourage innovation as the core, and guide the healthy development of the pharmaceutical industry. For failure to adopt new technologies to improve Drug Quality And security, a simple change in dosage form of product registration applications should be approved.
The e-commerce company in China offers quality products such as Turned parts , Sheet Metal Parts Supplier, and more. For more , please visit machining parts Manufacturer today!
Processing your request, Please wait....
